2025 Q3 -tulosraportti
64 päivää sitten1 t 51 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10. | |
| 2025 Q2 -tulosraportti | 16.7. | |
| 2025 Q1 -tulosraportti | 6.5. | |
| 2024 Q4 -tulosraportti | 6.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenSTOCKHOLM (Nyhetsbyrån Direkt) Following the sale of the US rights for Zubsolv, Orexo has the resources to take its current projects into the next phase, but the company will also look at opportunities for partnership agreements going forward. This is according to Orexo's CEO Nikolaj Sørensen in an interview with Nyhetsbyrån Direkt after the deal where the US rights to Zubsolv are sold to Dexcel Pharma for 91 million dollars plus an additional purchase price of up to 16.8 million dollars based on future sales. "We have the ability to bring our ongoing projects to fruition with the capital we receive. But we will also look at opportunities to finance new projects," he says. Following the sale of the drug Zubsolv, for opioid dependence, which accounts for 96 percent of the company's revenues, Orexo will become a more focused research company. The deal with Dexcel Pharma should be seen against the background that Orexo a year ago entered into a settlement agreement in a patent dispute which meant that generic versions of Zubsolv could enter the market in September 2030. "It's a good deal. We essentially secure the money we would earn from Zubsolv until 2030. After that, we expect revenues to decline dramatically from 2031 onwards." Nikolaj Sørensen explains that during the first half of this year, the company received proposals from companies interested in buying Zubsolv, whereupon the company initiated a process. "We have evaluated several different proposals. There are other companies that have submitted bids as well," he says. Going forward, Orexo now has the opportunity to focus on its ongoing and future projects. At the forefront is OX640, which is a nasal treatment for allergic reactions. "We have seen that there is great value for us to take OX640 a step further in development before we sign partnerships. The stage the project is currently in has not been attractive enough for potential partners." Are you having any discussions about OX640 now? "We have several companies that are interested, not least if we can produce a bit more data. Many large companies require us to test our finished product on healthy volunteers to demonstrate similar absorption in the body as an injection pen," says Nikolaj Sørensen, explaining that the company will begin producing the product on a commercial scale during the spring. The company is also running a project concerning OX390, for overdose caused by polysubstance abuse, together with the US agency Barda. "Even though Barda is financing almost the entire development, Orexo will participate in financing the project. Here, we have also ensured that resources are available throughout the project's duration until the early 2030s." Otherwise, Orexo will focus on its Amorphox platform for biological drugs. "We have tested it on semaglutide for weight loss, with promising results. But we would need to invest more money in that development. Through a nasal spray, there is an opportunity to achieve better absorption through the nose than if the drug is taken orally or via injection." How far off is this? "This is an early project, and I don't want to give a time perspective. Hopefully, it's in the short to medium term. We are in a phase where we have promising results that we want to build upon, and now we are getting the resources to do so." The Orexo CEO also wants to highlight that the company will remain in the US market through the OX390 project with Barda. "It is strategically important for us in the long term to be in the world's largest pharmaceutical market," he says.
·2 päivää sittenOh, what will happen today?
·4.12.DNB Carnegie has a justified value for Orexo at 27–35 kronor. Outside this valuation lies an agreement regarding OX640 or partnerships concerning other biomolecules that can be administered via the Amorpha platform. Orexo now has its revenue for Zubsolv relatively stable, as well as the agreement with Barda which guarantees coverage for the development of OX390 and provides some synergies within the company's personnel budget. So exciting things can come in 2026 and Carnegie writes about an upcoming eventful year. The stock has successively come down now due to a lack of news and guidance from the company, which has triggered disappointment among more short-term investors. But the latest rise clearly showed how fast it can go up for Orexo, and most signs indicate that we will get there again and further up during 2026. It could be the year when the company transforms into a company that does not rely so heavily on Zubsolv but becomes a broader pharmaceutical company. If orexo succeeds with this, larger investors will come in, and Carnegie writes about exactly this in its latest analysis. Like
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
64 päivää sitten1 t 51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenSTOCKHOLM (Nyhetsbyrån Direkt) Following the sale of the US rights for Zubsolv, Orexo has the resources to take its current projects into the next phase, but the company will also look at opportunities for partnership agreements going forward. This is according to Orexo's CEO Nikolaj Sørensen in an interview with Nyhetsbyrån Direkt after the deal where the US rights to Zubsolv are sold to Dexcel Pharma for 91 million dollars plus an additional purchase price of up to 16.8 million dollars based on future sales. "We have the ability to bring our ongoing projects to fruition with the capital we receive. But we will also look at opportunities to finance new projects," he says. Following the sale of the drug Zubsolv, for opioid dependence, which accounts for 96 percent of the company's revenues, Orexo will become a more focused research company. The deal with Dexcel Pharma should be seen against the background that Orexo a year ago entered into a settlement agreement in a patent dispute which meant that generic versions of Zubsolv could enter the market in September 2030. "It's a good deal. We essentially secure the money we would earn from Zubsolv until 2030. After that, we expect revenues to decline dramatically from 2031 onwards." Nikolaj Sørensen explains that during the first half of this year, the company received proposals from companies interested in buying Zubsolv, whereupon the company initiated a process. "We have evaluated several different proposals. There are other companies that have submitted bids as well," he says. Going forward, Orexo now has the opportunity to focus on its ongoing and future projects. At the forefront is OX640, which is a nasal treatment for allergic reactions. "We have seen that there is great value for us to take OX640 a step further in development before we sign partnerships. The stage the project is currently in has not been attractive enough for potential partners." Are you having any discussions about OX640 now? "We have several companies that are interested, not least if we can produce a bit more data. Many large companies require us to test our finished product on healthy volunteers to demonstrate similar absorption in the body as an injection pen," says Nikolaj Sørensen, explaining that the company will begin producing the product on a commercial scale during the spring. The company is also running a project concerning OX390, for overdose caused by polysubstance abuse, together with the US agency Barda. "Even though Barda is financing almost the entire development, Orexo will participate in financing the project. Here, we have also ensured that resources are available throughout the project's duration until the early 2030s." Otherwise, Orexo will focus on its Amorphox platform for biological drugs. "We have tested it on semaglutide for weight loss, with promising results. But we would need to invest more money in that development. Through a nasal spray, there is an opportunity to achieve better absorption through the nose than if the drug is taken orally or via injection." How far off is this? "This is an early project, and I don't want to give a time perspective. Hopefully, it's in the short to medium term. We are in a phase where we have promising results that we want to build upon, and now we are getting the resources to do so." The Orexo CEO also wants to highlight that the company will remain in the US market through the OX390 project with Barda. "It is strategically important for us in the long term to be in the world's largest pharmaceutical market," he says.
- ·2 päivää sittenOh, what will happen today?
- ·4.12.DNB Carnegie has a justified value for Orexo at 27–35 kronor. Outside this valuation lies an agreement regarding OX640 or partnerships concerning other biomolecules that can be administered via the Amorpha platform. Orexo now has its revenue for Zubsolv relatively stable, as well as the agreement with Barda which guarantees coverage for the development of OX390 and provides some synergies within the company's personnel budget. So exciting things can come in 2026 and Carnegie writes about an upcoming eventful year. The stock has successively come down now due to a lack of news and guidance from the company, which has triggered disappointment among more short-term investors. But the latest rise clearly showed how fast it can go up for Orexo, and most signs indicate that we will get there again and further up during 2026. It could be the year when the company transforms into a company that does not rely so heavily on Zubsolv but becomes a broader pharmaceutical company. If orexo succeeds with this, larger investors will come in, and Carnegie writes about exactly this in its latest analysis. Like
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10. | |
| 2025 Q2 -tulosraportti | 16.7. | |
| 2025 Q1 -tulosraportti | 6.5. | |
| 2024 Q4 -tulosraportti | 6.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
64 päivää sitten1 t 51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 23.10. | |
| 2025 Q2 -tulosraportti | 16.7. | |
| 2025 Q1 -tulosraportti | 6.5. | |
| 2024 Q4 -tulosraportti | 6.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenSTOCKHOLM (Nyhetsbyrån Direkt) Following the sale of the US rights for Zubsolv, Orexo has the resources to take its current projects into the next phase, but the company will also look at opportunities for partnership agreements going forward. This is according to Orexo's CEO Nikolaj Sørensen in an interview with Nyhetsbyrån Direkt after the deal where the US rights to Zubsolv are sold to Dexcel Pharma for 91 million dollars plus an additional purchase price of up to 16.8 million dollars based on future sales. "We have the ability to bring our ongoing projects to fruition with the capital we receive. But we will also look at opportunities to finance new projects," he says. Following the sale of the drug Zubsolv, for opioid dependence, which accounts for 96 percent of the company's revenues, Orexo will become a more focused research company. The deal with Dexcel Pharma should be seen against the background that Orexo a year ago entered into a settlement agreement in a patent dispute which meant that generic versions of Zubsolv could enter the market in September 2030. "It's a good deal. We essentially secure the money we would earn from Zubsolv until 2030. After that, we expect revenues to decline dramatically from 2031 onwards." Nikolaj Sørensen explains that during the first half of this year, the company received proposals from companies interested in buying Zubsolv, whereupon the company initiated a process. "We have evaluated several different proposals. There are other companies that have submitted bids as well," he says. Going forward, Orexo now has the opportunity to focus on its ongoing and future projects. At the forefront is OX640, which is a nasal treatment for allergic reactions. "We have seen that there is great value for us to take OX640 a step further in development before we sign partnerships. The stage the project is currently in has not been attractive enough for potential partners." Are you having any discussions about OX640 now? "We have several companies that are interested, not least if we can produce a bit more data. Many large companies require us to test our finished product on healthy volunteers to demonstrate similar absorption in the body as an injection pen," says Nikolaj Sørensen, explaining that the company will begin producing the product on a commercial scale during the spring. The company is also running a project concerning OX390, for overdose caused by polysubstance abuse, together with the US agency Barda. "Even though Barda is financing almost the entire development, Orexo will participate in financing the project. Here, we have also ensured that resources are available throughout the project's duration until the early 2030s." Otherwise, Orexo will focus on its Amorphox platform for biological drugs. "We have tested it on semaglutide for weight loss, with promising results. But we would need to invest more money in that development. Through a nasal spray, there is an opportunity to achieve better absorption through the nose than if the drug is taken orally or via injection." How far off is this? "This is an early project, and I don't want to give a time perspective. Hopefully, it's in the short to medium term. We are in a phase where we have promising results that we want to build upon, and now we are getting the resources to do so." The Orexo CEO also wants to highlight that the company will remain in the US market through the OX390 project with Barda. "It is strategically important for us in the long term to be in the world's largest pharmaceutical market," he says.
- ·2 päivää sittenOh, what will happen today?
- ·4.12.DNB Carnegie has a justified value for Orexo at 27–35 kronor. Outside this valuation lies an agreement regarding OX640 or partnerships concerning other biomolecules that can be administered via the Amorpha platform. Orexo now has its revenue for Zubsolv relatively stable, as well as the agreement with Barda which guarantees coverage for the development of OX390 and provides some synergies within the company's personnel budget. So exciting things can come in 2026 and Carnegie writes about an upcoming eventful year. The stock has successively come down now due to a lack of news and guidance from the company, which has triggered disappointment among more short-term investors. But the latest rise clearly showed how fast it can go up for Orexo, and most signs indicate that we will get there again and further up during 2026. It could be the year when the company transforms into a company that does not rely so heavily on Zubsolv but becomes a broader pharmaceutical company. If orexo succeeds with this, larger investors will come in, and Carnegie writes about exactly this in its latest analysis. Like
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt